Modification of bioabsorbable stent to reduce thrombogenecity
Bioabsorbable polymer scaffolds with coatings are disclosed that include immobilized antithrombotic agents on the scaffolds or in or on the coatings. The agents act synergistically with antiproliferative agents released from coatings by providing hemocompatibility during and without interfering with antiproliferative agent release. Methods of modifying scaffolds and coatings with the antithrombotic agents are disclosed.
1. A bioabsorbable stent comprising:
a poly(L-lactide) (PLLA) scaffolding composed of a plurality of struts having a thickness between 100 and 200 microns; and
a first coating layer disposed over the PLLA scaffolding and a second coating layer disposed over the first coating layer,
wherein each coating layer has a thickness less than 2 microns,
wherein each coating layer comprises a surface eroding polymer,
wherein the polymer is selected from the group consisting of hydrophobic aliphatic polyanhydrides, hydrophobic aromatic polyanhydrides, polyester amides, poly(ortho esters), and polyketals, and
wherein immobilized antithrombotic agent is at an outer surface of each coating layer, wherein the immobilized antithrombotic agent is heparin.
2. The stent of claim 1 , wherein an antiproliferative agent is distributed throughout each layer.
3. The stent of claim 1 , wherein the antithrombotic agent is immobilized only at an outer surface of each coating layer or penetrates into each coating layer by no more than 100 nm.
4. The stent of claim 1 , wherein the immobilized antithrombotic agent is immobilized by covalent bonds to the polymer at the outer surface of each coating layer.
5. The stent of claims 1 , wherein the antithrombotic agent is immobilized only at an outer surface of each coating layer or penetrates into each coating layer by no more than 100 nm, and wherein the immobilized antithrombotic agent is immobilized by covalent bonds to the polymer at the outer surface of each coating layer.
6. A bioabsorbable stent comprising:
a poly(L-lactide) (PLLA) scaffolding composed of a plurality of struts having a thickness between 100 and 200 microns; and
a first coating layer disposed over the PLLA scaffolding and a second coating layer disposed over the first coating layer,
wherein each coating layer has a thickness less than 2 microns,
wherein each coating layer comprises a surface eroding polymer,
wherein the polymer is selected from the group consisting of hydrophobic aliphatic polyanhydrides, hydrophobic aromatic polyanhydrides, polyester amides, poly(ortho esters), and polyketals,
wherein immobilized antithrombotic agent is at an outer surface of each coating layer,
wherein an antiproliferative agent is distributed throughout each layer, wherein the antiproliferative agent is selected from the group consisting of rapamycin, structural derivatives and functional analogues of rapamycin, paclitaxel, and taxol.
7. The stent of claim 6 , wherein the antithrombotic agent is selected from the group consisting of heparin, non-adhesive proteins, cell adhesive proteins, cell adhesive peptide sequences, and hydrophilic monomers or polymers.
8. The stent of claim 6 , wherein the antithrombotic agent is immobilized only at an outer surface of each coating layer or penetrates into each coating layer by no more than 100 nm.
9. The stent of claim 6 , wherein the immobilized antithrombotic agent is immobilized by covalent bonds to the polymer at the outer surface of each coating layer.
10. The stent of claim 6 , wherein the antithrombotic agent is immobilized only at an outer surface of each coating layer or penetrates into each coating layer by no more than 100 nm, and wherein the immobilized antithrombotic agent is immobilized by covalent bonds to the polymer at the outer surface of each coating layer.